Trial Profile

A Phase 2, Multicenter, Open-label, Proof-of-concept Study With Safety Run-in to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Adult Subjects With Basal Cell Carcinoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Nov 2025 Results presented in a Verrica Pharmaceuticals media release
10 Nov 2025 According to Verrica Pharmaceuticals media release, new data from phase 2 study evaluating VP-315 (ruxotemitide), presented at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting which took place November 5-9, 2025, in National Harbor, Maryland.
08 Oct 2025 According to Verrica Pharmaceuticals media release, data from the trial will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com